Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis

Youhyun Kim, Hyeok Choi, Seung Min Jung, Jason Jungsik Song, Yong Beom Park, Sang Won Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: We investigated whether systemic immune-inflammation index (SII) at diagnosis can estimate the cross-sectional high activity and predict the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: We retrospectively reviewed the medical records of 163 patients with AAV and obtained clinical and laboratory data. We calculated Birmingham vasculitis activity score (BVAS) as well as five-factor score (FFS) (2009) at diagnosis. SII at diagnosis was calculated by the equation of (SII at diagnosis = platelet count × neutrophil count/lymphocyte count at diagnosis). Severe AAV was defined as BVAS at diagnosis ≥16. The odds ratio was assessed using the multivariable logistic regression analysis and cumulative survival rates were compared by the Kaplan–Meier survival analysis. Results: The median age at diagnosis was 58.0 years old and 51 patients were men. The median BVAS was 12.0. Fifty-seven patients had severe AAV. The median SII at diagnosis was 1349.6. In the multivariable analysis, only SII exhibited a significant odds ratio for the cross-sectional severe AAV (P = 0.043). We obtained the cut-off of SII at diagnosis for severe AAV as 1573.56. Patients with SII at diagnosis ≥1573.56 exhibited a significantly high relative risk of the cross-sectional severe AAV compared to those without (relative risk 4.625). Furthermore, patients with SII at diagnosis ≥1573.56 exhibited significantly the lower cumulative relapse free and renal survivals than those without. Conclusion: Systemic immune-inflammation index at diagnosis could estimate the cross-section severe AAV and predict the poor outcomes in AAV patients.

Original languageEnglish
Pages (from-to)711-717
Number of pages7
JournalNephrology
Volume24
Issue number7
DOIs
Publication statusPublished - 2019 Jul

Fingerprint

Antineutrophil Cytoplasmic Antibodies
Immunosuppressive Agents
Vasculitis
Inflammation
Pharmaceutical Preparations
Antibodies
Odds Ratio
Lymphocyte Count
Survival Analysis
Platelet Count
Medical Records
Neutrophils
Survival Rate
Logistic Models

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

@article{d00bf0ebb24649919cc36d6e9751767b,
title = "Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-na{\"i}ve patients with antineutrophil cytoplasmic antibody-associated vasculitis",
abstract = "Objectives: We investigated whether systemic immune-inflammation index (SII) at diagnosis can estimate the cross-sectional high activity and predict the poor outcomes in immunosuppressive drug-na{\"i}ve patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: We retrospectively reviewed the medical records of 163 patients with AAV and obtained clinical and laboratory data. We calculated Birmingham vasculitis activity score (BVAS) as well as five-factor score (FFS) (2009) at diagnosis. SII at diagnosis was calculated by the equation of (SII at diagnosis = platelet count × neutrophil count/lymphocyte count at diagnosis). Severe AAV was defined as BVAS at diagnosis ≥16. The odds ratio was assessed using the multivariable logistic regression analysis and cumulative survival rates were compared by the Kaplan–Meier survival analysis. Results: The median age at diagnosis was 58.0 years old and 51 patients were men. The median BVAS was 12.0. Fifty-seven patients had severe AAV. The median SII at diagnosis was 1349.6. In the multivariable analysis, only SII exhibited a significant odds ratio for the cross-sectional severe AAV (P = 0.043). We obtained the cut-off of SII at diagnosis for severe AAV as 1573.56. Patients with SII at diagnosis ≥1573.56 exhibited a significantly high relative risk of the cross-sectional severe AAV compared to those without (relative risk 4.625). Furthermore, patients with SII at diagnosis ≥1573.56 exhibited significantly the lower cumulative relapse free and renal survivals than those without. Conclusion: Systemic immune-inflammation index at diagnosis could estimate the cross-section severe AAV and predict the poor outcomes in AAV patients.",
author = "Youhyun Kim and Hyeok Choi and Jung, {Seung Min} and Song, {Jason Jungsik} and Park, {Yong Beom} and Lee, {Sang Won}",
year = "2019",
month = "7",
doi = "10.1111/nep.13491",
language = "English",
volume = "24",
pages = "711--717",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley-Blackwell",
number = "7",

}

Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis. / Kim, Youhyun; Choi, Hyeok; Jung, Seung Min; Song, Jason Jungsik; Park, Yong Beom; Lee, Sang Won.

In: Nephrology, Vol. 24, No. 7, 07.2019, p. 711-717.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Systemic immune-inflammation index could estimate the cross-sectional high activity and the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis

AU - Kim, Youhyun

AU - Choi, Hyeok

AU - Jung, Seung Min

AU - Song, Jason Jungsik

AU - Park, Yong Beom

AU - Lee, Sang Won

PY - 2019/7

Y1 - 2019/7

N2 - Objectives: We investigated whether systemic immune-inflammation index (SII) at diagnosis can estimate the cross-sectional high activity and predict the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: We retrospectively reviewed the medical records of 163 patients with AAV and obtained clinical and laboratory data. We calculated Birmingham vasculitis activity score (BVAS) as well as five-factor score (FFS) (2009) at diagnosis. SII at diagnosis was calculated by the equation of (SII at diagnosis = platelet count × neutrophil count/lymphocyte count at diagnosis). Severe AAV was defined as BVAS at diagnosis ≥16. The odds ratio was assessed using the multivariable logistic regression analysis and cumulative survival rates were compared by the Kaplan–Meier survival analysis. Results: The median age at diagnosis was 58.0 years old and 51 patients were men. The median BVAS was 12.0. Fifty-seven patients had severe AAV. The median SII at diagnosis was 1349.6. In the multivariable analysis, only SII exhibited a significant odds ratio for the cross-sectional severe AAV (P = 0.043). We obtained the cut-off of SII at diagnosis for severe AAV as 1573.56. Patients with SII at diagnosis ≥1573.56 exhibited a significantly high relative risk of the cross-sectional severe AAV compared to those without (relative risk 4.625). Furthermore, patients with SII at diagnosis ≥1573.56 exhibited significantly the lower cumulative relapse free and renal survivals than those without. Conclusion: Systemic immune-inflammation index at diagnosis could estimate the cross-section severe AAV and predict the poor outcomes in AAV patients.

AB - Objectives: We investigated whether systemic immune-inflammation index (SII) at diagnosis can estimate the cross-sectional high activity and predict the poor outcomes in immunosuppressive drug-naïve patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: We retrospectively reviewed the medical records of 163 patients with AAV and obtained clinical and laboratory data. We calculated Birmingham vasculitis activity score (BVAS) as well as five-factor score (FFS) (2009) at diagnosis. SII at diagnosis was calculated by the equation of (SII at diagnosis = platelet count × neutrophil count/lymphocyte count at diagnosis). Severe AAV was defined as BVAS at diagnosis ≥16. The odds ratio was assessed using the multivariable logistic regression analysis and cumulative survival rates were compared by the Kaplan–Meier survival analysis. Results: The median age at diagnosis was 58.0 years old and 51 patients were men. The median BVAS was 12.0. Fifty-seven patients had severe AAV. The median SII at diagnosis was 1349.6. In the multivariable analysis, only SII exhibited a significant odds ratio for the cross-sectional severe AAV (P = 0.043). We obtained the cut-off of SII at diagnosis for severe AAV as 1573.56. Patients with SII at diagnosis ≥1573.56 exhibited a significantly high relative risk of the cross-sectional severe AAV compared to those without (relative risk 4.625). Furthermore, patients with SII at diagnosis ≥1573.56 exhibited significantly the lower cumulative relapse free and renal survivals than those without. Conclusion: Systemic immune-inflammation index at diagnosis could estimate the cross-section severe AAV and predict the poor outcomes in AAV patients.

UR - http://www.scopus.com/inward/record.url?scp=85060111195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060111195&partnerID=8YFLogxK

U2 - 10.1111/nep.13491

DO - 10.1111/nep.13491

M3 - Article

C2 - 30203901

AN - SCOPUS:85060111195

VL - 24

SP - 711

EP - 717

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 7

ER -